People with migraine face elevated risk of developing metabolic syndrome, creating a bidirectional health challenge that compounds both conditions. The research identifies obesity, hypertension, hypercoagulability, and diabetes as key metabolic factors that interplay with migraine pathophysiology. Notably, GLP-1 receptor agonists emerge as promising dual-purpose therapeutics, potentially addressing both migraine frequency and metabolic dysfunction simultaneously. This metabolic-neurological connection represents a paradigm shift in migraine understanding, moving beyond traditional neurological models to recognize systemic metabolic contributions. The implications are significant for the estimated 12% of adults with migraine, particularly those with treatment-resistant forms. Weight loss and structured exercise programs demonstrate strong evidence for reducing migraine frequency, suggesting lifestyle interventions may be as crucial as pharmacological approaches. For clinicians, this necessitates careful selection of migraine prophylactics, avoiding medications that promote weight gain in already metabolically vulnerable patients. The bidirectional relationship suggests that addressing metabolic health could break the cycle where migraine disability reduces physical activity, worsening metabolic parameters, which then exacerbate migraine severity—a therapeutic opportunity that extends beyond traditional headache medicine.